Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy.

MLA

Iannazzo, S., et al. “Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy.” Value in Health, vol. 16, no. 7, Nov. 2013, p. A344. EBSCOhost, https://doi.org/10.1016/j.jval.2013.08.132.

APA

Iannazzo, S., De Francesco, M., Coco, B., Brunetto, M., Tomic, R., Paolini, D., Palmieri, G., & Bonino, F. (2013). Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy. Value in Health, 16(7), A344. https://doi.org/10.1016/j.jval.2013.08.132

Chicago

Iannazzo, S., M. De Francesco, B. Coco, M. Brunetto, R. Tomic, D. Paolini, G. Palmieri, and F. Bonino. 2013. “Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy.” Value in Health 16 (7): A344. doi:10.1016/j.jval.2013.08.132.